{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T08:56:49Z","timestamp":1764233809362,"version":"3.46.0"},"reference-count":25,"publisher":"Georg Thieme Verlag KG","issue":"09","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Z Gastroenterol"],"published-print":{"date-parts":[[2024,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Carrilizumab, a PD-1 inhibitor, has shown therapeutic effectiveness in patients with late-stage or metastatic solid tumors exhibiting DNA mismatch repair deficiency (dMMR) or microsatellite instability-high (MSI-H). dMMR\/MSI-H cancer patients are known to be responsive to PD-1 inhibitors. However, the use of carrilizumab for preoperative immunotherapy in early, unresectable MSI-H\/dMMR primary colon cancer lesions is relatively underexplored. We present the case of a 46-year-old male who sought medical attention at our institution due to a history of hematochezia for two weeks, right-sided abdominal pain for one week, and loose stools. Imaging indicated duodenal involvement, and a biopsy confirmed ascending colon adenocarcinoma with MSI-H status. Given that the patient\u2019s family exhibited a history of more than three confirmed cases of colorectal cancer spanning two generations, Lynch syndrome was considered. After four cycles of PD-1 antagonist immunotherapy with carrilizumab, the patient\u2019s symptoms resolved, and physical examination revealed no abdominal tenderness or palpable masses. Following radical colectomy, the primary tumor exhibited a pathological complete response. This case highlights the potential of preoperative neoadjuvant immunotherapy to improve staging accuracy and increase surgical resection rates in T4b MSI-H colon cancer patients without distant metastasis, suggesting a need for reconsideration of the treatment approach.<\/jats:p>","DOI":"10.1055\/a-2258-8565","type":"journal-article","created":{"date-parts":[[2024,4,11]],"date-time":"2024-04-11T19:01:42Z","timestamp":1712862102000},"page":"1379-1383","source":"Crossref","is-referenced-by-count":0,"title":["Neoadjuvant immunotherapy in a locally advanced colon cancer patient with MSI-H and suspected Lynch syndrome: A case report"],"prefix":"10.1055","volume":"62","author":[{"given":"Xiaoyun","family":"Li","sequence":"first","affiliation":[{"name":"Department of Anorectal Surgery, The Affiliated Hospital of Guizhou Medical University, Guiyang, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yining","family":"Xiang","sequence":"first","affiliation":[{"name":"Department of Pathology, The Affiliated Hospital of Guizhou Medical University, Guiyang, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunhuan","family":"Zhen","sequence":"additional","affiliation":[{"name":"Department of Anorectal Surgery, The Affiliated Hospital of Guizhou Medical University, Guiyang, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong","family":"Yu","sequence":"additional","affiliation":[{"name":"Guiyang Public Health Clinical Center, Guiyang, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2024,4,11]]},"reference":[{"issue":"01","key":"ref1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21654","article-title":"Cancer Statistics, 2021","volume":"71","author":"RL Siegel","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"01","key":"ref2","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s40880-019-0368-6","article-title":"Current cancer situation in China: good or bad news from the 2018 Global Cancer Statistics?","volume":"39","author":"RM Feng","year":"2019","journal-title":"Cancer Commun (Lond)"},{"issue":"11","key":"ref3","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1002\/ijc.25265","article-title":"Combined analysis of specific KRAS mutation, BRAF and microsatellite instability identifies prognostic subgroups of sporadic and hereditary colorectal cancer","volume":"127","author":"I Zlobec","year":"2010","journal-title":"Int J Cancer"},{"issue":"01","key":"ref4","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1093\/annonc\/mdx738","article-title":"Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO-ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS","volume":"29","author":"T Yoshino","year":"2018","journal-title":"Annals of Oncology"},{"issue":"04","key":"ref5","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1200\/JCO.18.00283","article-title":"Microsatellite instability is associated with the presence of Lynch syndrome pan-cancer","volume":"37","author":"A Latham","year":"2019","journal-title":"J Clin Oncol"},{"issue":"01","key":"ref6","doi-asserted-by":"publisher","first-page":"73","DOI":"10.4161\/cbt.3.1.590","article-title":"Evaluation of microsatellite instability, hMLH1 expression and hMLH1 promoter hypermethylation in defining the MSI phenotype of colorectal cancer","volume":"3","author":"CN Arnold","year":"2004","journal-title":"Cancer Biol Ther"},{"issue":"06","key":"ref7","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1053\/j.gastro.2012.09.032","article-title":"Epigenetics of colorectal cancer","volume":"143","author":"A Goel","year":"2012","journal-title":"Gastroenterology"},{"issue":"07","key":"ref8","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1080\/17474124.2021.1886077","article-title":"Defining the current role of immune checkpoint inhibitors in the treatment of mismatch repair-deficient\/microsatellite stability-high colorectal cancer and shedding light on future approaches","volume":"15","author":"E Tan","year":"2021","journal-title":"Expert Rev Gastroenterol Hepatol"},{"issue":"01","key":"ref9","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s12943-021-01489-2","article-title":"Combination strategies with PD-1\/PD-L1 blockade: current advances and future directions","volume":"21","author":"M Yi","year":"2022","journal-title":"Mol Cancer"},{"issue":"10","key":"ref10","doi-asserted-by":"publisher","first-page":"2651","DOI":"10.1200\/JCO.19.02105","article-title":"Camrelizumab in advanced or metastatic solid tumour patients with DNA mismatch repair deficient or microsatellite instability high: an open-label prospective pivotal trial","volume":"146","author":"J Chen","year":"2020","journal-title":"J Cancer Res Clin Oncol"},{"issue":"11","key":"ref11","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1016\/S1470-2045(12)70348-0","article-title":"Feasibility of preoperative chemotherapy for locally advanced, operable colon cancer: the pilot phase of a randomised controlled trial","volume":"13","author":"Foxtrot Collaborative Group","year":"2012","journal-title":"The Lancet"},{"issue":"23","key":"ref12","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1056\/NEJMoa2017699","article-title":"Pembrolizumab in microsatellite-instability-high advanced colorectal cancer","volume":"383","author":"T Andr\u00e9","year":"2020","journal-title":"N Engl J Med"},{"issue":"09","key":"ref13","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1016\/S1470-2045(17)30422-9","article-title":"Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study","volume":"18","author":"MJ Overman","year":"2017","journal-title":"Lancet Oncol"},{"issue":"01","key":"ref14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: Results from the phase II KEYNOTE-158 study","volume":"38","author":"A Marabelle","year":"2020","journal-title":"J Clin Oncol"},{"issue":"26","key":"ref15","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 Blockade in Tumors with Mismatch-Repair Deficiency","volume":"372","author":"DT Le","year":"2015","journal-title":"N Engl J Med"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"DT Le","year":"2017","journal-title":"Science"},{"issue":"11","key":"ref17","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1038\/s41591-019-0628-7","article-title":"Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial","volume":"25","author":"T Powles","year":"2019","journal-title":"Nat Med"},{"issue":"03","key":"ref18","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1038\/s41591-019-0357-y","article-title":"A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma","volume":"25","author":"AC Huang","year":"2019","journal-title":"Nat Med"},{"issue":"21","key":"ref19","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.1056\/NEJMoa1716078","article-title":"Neoadjuvant PD-1 Blockade in Resectable Lung Cancer","volume":"378","author":"PM Forde","year":"2018","journal-title":"N Engl J Med"},{"issue":"11","key":"ref20","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1038\/s41591-018-0198-0","article-title":"Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma","volume":"24","author":"CU Blank","year":"2018","journal-title":"Nat Med"},{"issue":"11","key":"ref21","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1038\/s41591-018-0197-1","article-title":"Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma","volume":"24","author":"RN Amaria","year":"2018","journal-title":"Nat Med"},{"issue":"12","key":"ref22","doi-asserted-by":"crossref","first-page":"e2110","DOI":"10.1002\/onco.13955","article-title":"Complete Pathological Response After Neoadjuvant Short-Course Immunotherapy with Ipilimumab and Nivolumab in Locally Advanced MSI-H\/dMMR Rectal Cancer","volume":"26","author":"J Trojan","year":"2021","journal-title":"Oncologist"},{"issue":"07","key":"ref23","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1093\/oncolo\/oyac095","article-title":"Response to Nivolumab and Ipilimumab in Microsatellite Instability-High (MSI-H) Cervical Carcinoma with Acquired Resistance to Pembrolizumab: A Case Report and Literature Review","volume":"27","author":"G Gim","year":"2022","journal-title":"Oncologist"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.2147\/OTT.S298333","article-title":"Complete Pathologic Response After Concurrent Treatment with Pembrolizumab and Radiotherapy in Metastatic Colorectal Cancer: A Case Report","volume":"14","author":"J Yang","year":"2021","journal-title":"Onco Targets Ther"},{"issue":"11","key":"ref25","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1038\/s41591-018-0250-0","article-title":"Is earlier better for melanoma checkpoint blockade?","volume":"24","author":"C Robert","year":"2018","journal-title":"Nat Med"}],"container-title":["Zeitschrift f\u00fcr Gastroenterologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2258-8565.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T08:53:45Z","timestamp":1764233625000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2258-8565"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,11]]},"references-count":25,"journal-issue":{"issue":"09","published-online":{"date-parts":[[2024,9,9]]},"published-print":{"date-parts":[[2024,9]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2258-8565","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0044-2771","1439-7803"],"issn-type":[{"type":"print","value":"0044-2771"},{"type":"electronic","value":"1439-7803"}],"subject":[],"published":{"date-parts":[[2024,4,11]]}}}